CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. today announced the transition of Cindy Perettie, Chief Executive Officer, to Roche Diagnostics to lead the Molecular Lab Solutions business headquartered in Pleasanton, California effective April 6, 2021.
Ms. Perettie was appointed CEO of Foundation Medicine in February 2019. Under her leadership, Foundation Medicine has expanded its leading position in comprehensive genomic cancer testing and in providing molecular insights for clinicians and the biopharma industry to transform cancer care. During her tenure, Foundation Medicine received FDA approval for its FoundationOne®Liquid CDx companion diagnostic test, which analyzes the largest genomic region of any FDA-approved comprehensive liquid biopsy test, signed a partnership with Natera, Inc for the joint development and commercialization of personalized circulating tumor DNA monitoring assays, acquired Lexent Bio to further accelerate research and development in early cancer diagnostics, and established global partnerships with providers and the biopharma industry to advance precision medicine and improve patient care and outcomes in oncology.
Prior to taking the helm at Foundation Medicine, Ms. Perettie served in multiple leadership roles with Roche and Genentech, most recently as senior vice president with product strategy responsibility for the global oncology portfolio. Before joining the Roche Group, she led global portfolio management for IVAX Pharmaceuticals, was the President of Global Development Innovations for the Sarah Cannon Research Institute based in Nashville, Tennessee, and served as Director of Global Program Management at Élan Corporation based in the United Kingdom. Ms. Perettie holds a master’s degree of marketing and finance from St. Mary’s College of California and received her bachelor’s degree in biology, with a minor in chemistry, from State University of New York College at Potsdam.
“Cindy’s business impact and leadership excellence are evident in what she and her team have achieved during her nearly two-year tenure. Coupled with her extensive scientific and commercial experience, Cindy has expanded Foundation Medicine’s industry-leading position in providing molecular insights to advance cancer research and clinical care,” said Severin Schwan, CEO, Roche Group. “She will be pivotal for the further transformation of our business and the next generation of Diagnostics solutions. My sincere thanks to Cindy and her team for all that they have already contributed for the benefit of patients and healthcare systems.”
Brian Alexander, M.D., M.P.H., Foundation Medicine’s Senior Vice President and Chief Medical Officer, will become the interim leader for the company after April 6 and ensure a smooth transition until a successor is in place.
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.
Source: Foundation Medicine
Bo Piela, [email protected]